PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study
Launched by BOSTON SCIENTIFIC CORPORATION · Jun 21, 2010
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • According to Instructions For Use
- Exclusion Criteria:
- • Contraindications according to Instructions for Use
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Galway, , Ireland
Toulouse, , France
Odense, , Denmark
Bonn, Nrw, Germany
Rouen, , France
Pavia, , Italy
London, , United Kingdom
Milano, , Italy
Cardiff, , United Kingdom
Hannover, , Germany
Bad Berka, , Germany
Ollioules, , France
Vienna, , Austria
Dordrecht, , Netherlands
Hasselt, , Belgium
Bad Segeberg, , Germany
Cambridge, , United Kingdom
Roskilde, , Denmark
Darmstadt, , Germany
Wels, , Austria
Dublin, , Ireland
London, , United Kingdom
Barcelona, , Spain
Dublin, , Ireland
Toulouse, , France
Linz, , Austria
Liege, , Belgium
Caen, , France
Le Plessis Robinson, , France
Pessac, , France
Düsseldorf, Nrw, Germany
Leverkusen, Nrw, Germany
Villingen Schwenningen, , Germany
Szeged, , Hungary
Dublin, , Ireland
Bergamo, , Italy
Napoli, , Italy
'S Hertogenbosch, , Netherlands
Nijmegen, , Netherlands
Newcastle Upon Tyne, , United Kingdom
Patients applied
Trial Officials
Raul Moreno, MD PhD
Principal Investigator
Hospital La Paz, Spain
Peter Maurer, PhD
Study Director
Boston Scientific Corporation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials